|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
CAMARILLA PIVOT POINT
Signal Strength: MEDIUM
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.
Mesoblast (ASX:MSB) current pivot point Camarilla is: $1.785.
The current resistance levels are: (R1) $1.934
The current support levels are: (S1) $1.636
Camarilla pivot points were discovered in 1989 by Nick Scott, a successful bond trader. The basic thesis for this strategy is a common one: That price, as most time series, has a tendency to revert to its mean.
Calculation: Camarilla Pivot Points:
1) R4 = Close + (High – Low) * 1.1/2;
2) R3 = Close + (High – Low) * 1.1/4;
3) R2 = Close + (High – Low) * 1.1/6;
4) R1 = Close + (High – Low) * 1.1/12;
5) PP = (HIGH + LOW + CLOSE) / 3;
6) S1 = Close – (High – Low) * 1.1/12;
7) S2 = Close – (High – Low) * 1.1/6;
8) S3 = Close – (High – Low) * 1.1/4;
9) S4 = Close – (High – Low) * 1.1/2;
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|TNE Technology One||8.72||11.1||2,344,237||-0.02||BEARISH CROSSOVER|
|DNK Danakali||0.64||8.5||171,076||-0.03||BEARISH CROSSOVER|
|BSE BSE||0.24||6.8||118,988||-0.06||BEARISH CROSSOVER|
|CCV Cash Converters International||0.25||6.5||1,327,868||-0.02||BEARISH CROSSOVER|
|ALL Aristocrat Leisure||33.71||6||3,327,758||-0.01||BEARISH CROSSOVER|
|MLD Maca||1.07||5.9||822,651||-0.01||BEARISH CROSSOVER|
|ELX Ellex Medical Lasers||0.6||5.3||7,482||0||BEARISH CROSSOVER|
|IPD Impedimed||0.2||5.3||1,022,395||-0.03||BEARISH CROSSOVER|
|CDD Cardno||0.47||4.4||241,998||-0.03||BEARISH CROSSOVER|
|PPC Peet & Company||1.28||3.7||84,175||-0.01||BEARISH CROSSOVER|